Arcticzymes Technologies ASA - Asset Resilience Ratio

Latest as of December 2025: 21.29%

Arcticzymes Technologies ASA (AZT) has an Asset Resilience Ratio of 21.29% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore Arcticzymes Technologies ASA (AZT) total assets for the complete picture of this company's asset base.

Liquid Assets

Nkr76.94 Million
≈ $8.10 Million USD Cash + Short-term Investments

Total Assets

Nkr361.41 Million
≈ $38.03 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Arcticzymes Technologies ASA's Asset Resilience Ratio has changed over time. See Arcticzymes Technologies ASA (AZT) net asset quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Arcticzymes Technologies ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AZT market cap.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Nkr0.00 0%
Short-term Investments Nkr76.94 Million 21.29%
Total Liquid Assets Nkr76.94 Million 21.29%

Asset Resilience Insights

  • Good Liquidity Position: Arcticzymes Technologies ASA maintains a healthy 21.29% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Arcticzymes Technologies ASA Industry Peers by Asset Resilience Ratio

Compare Arcticzymes Technologies ASA's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Royalty Pharma Plc
NASDAQ:RPRX
Biotechnology 0.11%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Innovita Biological Technology Co. Ltd. A
SHG:688253
Biotechnology 65.12%
Hyundai Bioscience Co. Ltd
KQ:048410
Biotechnology 13.57%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 82.25%
Lifecome Biochemistry Co Ltd
SHE:002868
Biotechnology 4.69%
Sunmax Biotechnology Co Ltd
TWO:4728
Biotechnology 10.53%

Annual Asset Resilience Ratio for Arcticzymes Technologies ASA (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Arcticzymes Technologies ASA.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 21.29% Nkr76.94 Million
≈ $8.10 Million
Nkr361.41 Million
≈ $38.03 Million
-49.57pp
2024-12-31 70.86% Nkr243.94 Million
≈ $25.67 Million
Nkr344.26 Million
≈ $36.23 Million
+17.55pp
2023-12-31 53.31% Nkr180.89 Million
≈ $19.04 Million
Nkr339.32 Million
≈ $35.71 Million
-23.22pp
2022-12-31 76.53% Nkr244.16 Million
≈ $25.69 Million
Nkr319.04 Million
≈ $33.57 Million
+5.99pp
2021-12-31 70.54% Nkr200.42 Million
≈ $21.09 Million
Nkr284.11 Million
≈ $29.90 Million
+7.38pp
2020-12-31 63.17% Nkr140.18 Million
≈ $14.75 Million
Nkr221.91 Million
≈ $23.35 Million
+22.85pp
2019-12-31 40.32% Nkr31.29 Million
≈ $3.29 Million
Nkr77.61 Million
≈ $8.17 Million
-6.24pp
2018-12-31 46.55% Nkr31.66 Million
≈ $3.33 Million
Nkr68.02 Million
≈ $7.16 Million
-3.05pp
2017-12-31 49.60% Nkr30.59 Million
≈ $3.22 Million
Nkr61.68 Million
≈ $6.49 Million
-17.60pp
2016-12-31 67.19% Nkr57.67 Million
≈ $6.07 Million
Nkr85.83 Million
≈ $9.03 Million
--
pp = percentage points

About Arcticzymes Technologies ASA

OL:AZT Norway Biotechnology
Market Cap
$106.41 Million
Nkr1.01 Billion NOK
Market Cap Rank
#19076 Global
#167 in Norway
Share Price
Nkr19.80
Change (1 day)
-0.50%
52-Week Range
Nkr15.15 - Nkr30.90
All Time High
Nkr111.00
About

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays for the removal… Read more